Article
Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population.
Fundamental & clinical pharmacology - 1 Dec 2016
Xavier Alphienes Stanley, Kumar Saka Vinod, Sundaram Rajan, Francis Jose, Shewade Deepak Gopal
Abstract excerpt
Patients on antituberculosis therapy (ATT) are more prone to drug interactions in the presence of coexisting illnesses which require drug therapy. Rifampicin is a pleiotropic inducer of CYP enzymes, and isoniazid is an enzyme inhibitor. Genetic variations are common in the gene coding for CYP2C19 enzyme. These variations would be important in predicting the individual variations in CYP2C19 activity. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.